[Effect of tangshen formula on phospholipids metabolism in diabetic nephropathy patients].
This study was to report the effect of Tangshen Formula on phospholipids metabolism in diabetic nephropathy patients. A normal phase-HPLC-TOF/MS method was used in this study for the determination of seven species of phospholipids in human plasma. Then, the concentration changes of potential phospholipids biomarkers were discussed in diabetic nephropathy phase III and phase IV patients among different groups, including before and 3, 6 months after administration of Tangshen Formula. Significant increases of PE750, PI885, PC792, PC826, PC830, PC854 and PC802 levels were observed 6 months after administration of Tangshen Formula and conventional western medicine, as well as a decrease of LPC540 level, when compared with those before medication. Concentrations of all the potential phospholipids biomarkers showed a tendency towards normal levels; however, both the improvement degree and onset time of these compounds were not same. Additionally, Tangshen Formula treatment based on conventional western medicine treatment was more efficient in adjusting the levels of these compounds when compared with western medicine treatment alone, especially for the phase IV patients. These results indicated that Tangshen Formula was capable in regulating and improving phospholipids metabolism in diabetic nephropathy patients, which may be related with the direct or indirect inhibition of protein kinase C pathway and the corresponding reduction of phospholipase A2 activity. Therefore, Tangshen Formula may be used as an effective drug for diabetic nephropathy therapy, at least as an adjunctive therapeutic drug.
School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Min
M
Huang
Chao
C
Zhu
Qiong-Lin
QL
Liang
Ping
P
Li
Jing
J
Li
Yi-Ming
YM
Wang
Guo-An
GA
Luo
D003928:Diabetic Nephropathies / Q000097:blood* / Q000378:metabolism; D004311:Double-Blind Method; D004365:Drugs, Chinese Herbal / Q000302:isolation & purification / Q000494:pharmacology*; D020404:Glycerophospholipids / Q000097:blood; D006801:Humans; D008244:Lysophosphatidylcholines / Q000097:blood; D054467:Phospholipases A2 / Q000378:metabolism; D010743:Phospholipids / Q000097:blood* / Q000145:classification; D010946:Plants, Medicinal / Q000737:chemistry*; D011493:Protein Kinase C / Q000378:metabolism; D015398:Signal Transduction; D013109:Sphingomyelins / Q000097:blood
D004365:Drugs, Chinese Herbal; D020404:Glycerophospholipids; D008244:Lysophosphatidylcholines; D010743:Phospholipids; D013109:Sphingomyelins; D011493:Protein Kinase C; D054467:Phospholipases A2